Immunic Showcases Promising Vidofludimus Calcium Data at ECTRIMS 2025

Immunic, Inc., a leading biotechnology firm, recently presented pivotal data on Vidofludimus Calcium during the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Barcelona from September 24-26, 2025. This innovative treatment is being developed for patients with multiple sclerosis (MS) and has displayed significant potential in clinical trials.

At the congress, the data from the Phase 2 CALLIPER trial were particularly noteworthy. This trial evaluated the efficacy of Vidofludimus Calcium in reducing disability in patients suffering from progressive forms of multiple sclerosis. According to the presentation, patients who received Vidofludimus Calcium exhibited a statistically significant improvement in their condition over a 24-week period, doubling the probability of disability improvement compared to those on a placebo. This suggests that Vidofludimus Calcium could actively contribute to slowing the progression of this debilitating disease.

Dr. Daniel Vitt, the CEO of Immunic, emphasized the significance of presenting at such a prestigious gathering, noting that it highlights the robust clinical and preclinical data supporting the drug's efficacy. The CALLIPER trial's findings are particularly encouraging as they demonstrate consistent positive effects across varied disability endpoints, patient demographics, and even among subgroups that exhibit no evidence of focal inflammation. This showcases the neuroprotective aspects of Vidofludimus Calcium, indicating its promise not only in managing symptoms but potentially in altering the disease's trajectory.

Alongside the CALLIPER trial results, long-term data from the Phase 2 EMPhASIS trial were also shared. This trial focused on relapsing-remitting multiple sclerosis and demonstrated that a significant majority of patients continued to show no confirmed disability worsening after up to 144 weeks of treatment. The safety profile of Vidofludimus Calcium appears favorable, with low rates of discontinuation and mild side effects, reinforcing its suitability as a therapeutic option for MS patients.

The scientific community is particularly interested in the activation of the Nurr1 pathway by Vidofludimus Calcium. This mechanism could potentially protect against neurodegeneration—the main concern in MS progression. As the CALLIPER trial data displayed a strong correlation between Nurr1 activation and improved patient outcomes, further investigation into this novel mechanism is warranted. This could pave the way for innovative treatments that fundamentally change how multiple sclerosis is approached.

The culmination of this data suggests that Vidofludimus Calcium could be more than just another therapy in the crowded MS market. With its dual-action approach as both a neuroprotective and anti-inflammatory agent, it offers a unique blend of benefits that could challenge traditional MS treatments. As Immunic prepares for upcoming Phase 3 trials, the excitement surrounding Vidofludimus Calcium grows, particularly given the promising initial results. Top-line data from the Phase 3 ENSURE trials for relapsing multiple sclerosis are expected by the end of 2026, and there is optimism that these results will continue to support Vidofludimus Calcium's efficacy and safety profile.

In summary, the new findings from Immunic presented at ECTRIMS 2025 showcase Vidofludimus Calcium as a potential game-changer in the treatment landscape for multiple sclerosis. With continued research and promising early data, both healthcare professionals and patients have reason to be hopeful about advancements in effectively managing this challenging condition.